# Libtayo® (cemiplimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cemiplimab

> The next catalyst for Libtayo® (cemiplimab), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its interim data readout, late 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Libtayo® (cemiplimab) |
| Codes | REGN2810 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Cutaneous Squamous Cell Carcinoma (CSCC)](https://sec-api.dev/indications/cutaneous-squamous-cell-carcinoma-cscc), [Cutaneous Squamous Cell Carcinoma](https://sec-api.dev/indications/cutaneous-squamous-cell-carcinoma), [Melanoma](https://sec-api.dev/indications/melanoma), [Locally Advanced Basal Cell Carcinoma](https://sec-api.dev/indications/locally-advanced-basal-cell-carcinoma) |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### September 2025: primary completion

- Status: delayed. Date confidence: month. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04050436 (Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-09 (ESTIMATED); Lead Sponsor Replimune, Inc.." https://clinicaltrials.gov/study/NCT04050436

### Oct 2025: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2025-08-01, last confirmed 2025-08-01.
- Press release filed with the SEC (EX-99) (accession 0000872589-25-000017): "•The FDA accepted for priority review a supplemental Biologics License Application (sBLA) for Libtayo (cemiplimab) in adjuvant CSCC, with a target action date in October 2025." https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06190951

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Melanoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-02 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06190951

### late 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-08-05, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001790340-26-000095): "•4Q 2026: Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in lung cancer, with a preliminary data readout expected in late-2027." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000095/imrx-20261029xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001790340-26-000088): "•2H 2026: Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in non-small cell lung cancer, with a preliminary data readout expected in late-2027." https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cutaneous Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03969004 (Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT03969004

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cutaneous Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03969004 (Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT03969004

### May to Aug 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cutaneous Squamous Cell Carcinoma (CSCC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06585410 (Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06585410

### May 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cutaneous Squamous Cell Carcinoma (CSCC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06585410 (Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT06585410

### Nov 2030 to Feb 2031: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Locally Advanced Basal Cell Carcinoma.
- First seen 2026-11-13T10:20:01.295Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07808515 (A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07808515

### November 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Locally Advanced Basal Cell Carcinoma.
- First seen 2026-11-13T10:20:01.295Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07808515 (A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07808515

## Same indication

- [ABP-206](https://sec-api.dev/pdufa/abp-206) (AMGN)
- [Brentuximab vedotin](https://sec-api.dev/pdufa/brentuximab-vedotin) (PFE)
- [Encorafenib](https://sec-api.dev/pdufa/encorafenib) (PFE)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [Fianlimab+cemiplimab](https://sec-api.dev/pdufa/fianlimab-cemiplimab) (REGN)
- [INCB099280](https://sec-api.dev/pdufa/incb099280) (INCY)
- [RHUPH20](https://sec-api.dev/pdufa/rhuph20) (BMY)
- [KISQALI® (ribociclib)](https://sec-api.dev/pdufa/ribociclib) (NVS)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [January 2028](https://sec-api.dev/fda-calendar/2028-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cemiplimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Libtayo® (cemiplimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cemiplimab

```bibtex
@misc{secapidev_pdufa_cemiplimab_20261116,
  title        = {Libtayo® (cemiplimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cemiplimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cemiplimab_20261116","title":"Libtayo® (cemiplimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cemiplimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
